Gilead secured long-awaited US approval for its hepatitis D treatment Hepcludex (bulevirtide), roughly four years after the FDA previously rejected the drug over manufacturing and distribution concerns. The clearance resolves the earlier pathway block tied to quality and supply-chain issues. The approval matters for clinicians managing chronic hepatitis D, where treatment options remain constrained and where regulatory acceptance of manufacturing and logistics requirements can determine real-world availability. For Gilead, it also establishes a clearer commercialization runway after the prior denial and subsequent remediation cycle. The decision highlights how regulatory outcomes can hinge on operational control points even when the clinical value of a therapy is already established.